Search results
FDA approves first RSV vaccine for at-risk adults in their 50s
CBS News· 6 days agoFurther trials are planned looking at adults between 18 and 49 years old, GSK said, with results...
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
CNBC· 6 days agoThe Food and Drug Administration on Friday expanded the approval of GSK's respiratory syncytial...
Moderna's COVID-flu combo shot outperformed existing vaccines in a late-stage trial
Quartz· 4 days agoModerna said on Monday that its experimental combination vaccines against COVID-19 and the flu...
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Medscape· 4 days agoEncouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis...
Chronotherapy: Why Timing Drugs to Our Body Clocks May Work
Medscape· 4 days agoA new analysis published in this month's issue of The Lancet journal's eClinicalMedicine suggests:...
COVID-flu combo vaccine shows ‘positive’ results in phase 3 trials, Moderna says: A 'two-for' option
Fox News via Yahoo News· 3 days agoModerna, which is developing a combination COVID-flu vaccine, announced on Monday that in phase 3...
COVID-flu combo vaccine shows ‘positive’ results in phase 3 trials, Moderna says: A 'two-for' option
Fox News· 3 days agoA combination COVID-influenza vaccine is apparently one step closer to hitting the market. Moderna,...
Paxlovid Fails First Test in Long COVID
MedPage Today· 7 days agoA 15-day course of the antiviral nirmatrelvir-ritonavir (Paxlovid) didn't improve symptoms of long COVID, according to a randomized controlled trial that...
2-in-1 shot for flu and COVID shows promise in advanced trial
LiveScience· 3 days agoThe ongoing clinical trial pits this new combination shot, called mRNA-1083, against several licensed vaccines that protect against either COVID-19 or the flu. Compared with these separate vaccines ...
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and...
KOLR - KSFX Ozarks· 17 hours agoProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by ...